IL310354A - Water-soluble prodrug, couplers and their use - Google Patents

Water-soluble prodrug, couplers and their use

Info

Publication number
IL310354A
IL310354A IL310354A IL31035424A IL310354A IL 310354 A IL310354 A IL 310354A IL 310354 A IL310354 A IL 310354A IL 31035424 A IL31035424 A IL 31035424A IL 310354 A IL310354 A IL 310354A
Authority
IL
Israel
Prior art keywords
moiety
conjugate
compound
oligo
auristatin
Prior art date
Application number
IL310354A
Other languages
English (en)
Hebrew (he)
Inventor
Doron Shabat
Ronit Satchi-Fainaro
Stanley Sweeney-Lasch
Carl Deutsch
Nir Berger
Original Assignee
Univ Ramot
Merck Patent Gmbh
Doron Shabat
Satchi Fainaro Ronit
Sweeney Lasch Stanley
Carl Deutsch
Nir Berger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot, Merck Patent Gmbh, Doron Shabat, Satchi Fainaro Ronit, Sweeney Lasch Stanley, Carl Deutsch, Nir Berger filed Critical Univ Ramot
Publication of IL310354A publication Critical patent/IL310354A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL310354A 2021-07-28 2022-07-20 Water-soluble prodrug, couplers and their use IL310354A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL28520821 2021-07-28
PCT/IL2022/050782 WO2023007481A1 (en) 2021-07-28 2022-07-20 Water soluble prodrug, conjugates and uses thereof

Publications (1)

Publication Number Publication Date
IL310354A true IL310354A (en) 2024-03-01

Family

ID=85086377

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310354A IL310354A (en) 2021-07-28 2022-07-20 Water-soluble prodrug, couplers and their use

Country Status (7)

Country Link
EP (1) EP4377292A1 (https=)
JP (1) JP2024532677A (https=)
CN (1) CN117999254A (https=)
AU (1) AU2022318483A1 (https=)
CA (1) CA3226393A1 (https=)
IL (1) IL310354A (https=)
WO (1) WO2023007481A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4566631A1 (en) * 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201701128YA (en) * 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
CN120682290A (zh) * 2017-07-04 2025-09-23 尹图赛利有限公司 包含可裂解接头的化合物及其用途
JP7708662B2 (ja) * 2018-10-24 2025-07-15 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法

Also Published As

Publication number Publication date
CN117999254A (zh) 2024-05-07
EP4377292A1 (en) 2024-06-05
AU2022318483A1 (en) 2024-02-22
JP2024532677A (ja) 2024-09-10
WO2023007481A1 (en) 2023-02-02
CA3226393A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
AU2022204013B2 (en) Targeted delivery of tertiary amine-containing drug substances
JP7257951B2 (ja) 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート
JP7620991B6 (ja) 標的送達及び活性化した免疫刺激性複合体の調製と使用
TWI814699B (zh) 四級胺化妥布賴森(tubulysin)化合物之結合物
AU2022204711B9 (en) Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation
TWI900494B (zh) 從生物活性化合物的內化共軛物選擇性釋出藥物
CN112752759A (zh) 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物及其方法与用途
CN103379912B (zh) 正羧烷基耳他汀及其应用
CN106170303A (zh) 通过半胱天冬酶激活的前体药物
WO2016173682A1 (en) Conjugate of monomethyl auristatin f and trastuzumab and its use for the treatment of cancer
JP2018512376A (ja) 抗体薬物コンジュゲート
TW202506105A (zh) 連接子-藥物分子及抗體藥物偶聯物、其製備方法和應用
IL310354A (en) Water-soluble prodrug, couplers and their use
WO2025031923A1 (en) Imidazo[4,5-d]pyridazine compounds and conjugates thereof, their preparation, and their therapeutic applications
HK40111022A (zh) 水溶性前药、偶联物及其用途
US9669106B2 (en) Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer
WO2025077572A1 (zh) 一种用于前药给药系统的可裂解连接体化合物及其制备和应用
KR20240016231A (ko) 신규 오리스타틴 전구약물
TW202613076A (zh) 鏈接子-有效負載、由其作成之抗體-藥物共軛物及其用途
CN121449623A (zh) 一种拓扑异构酶抑制剂及其偶联物的应用
HK40065994A (zh) 含叔胺药物物质的靶向递送
HK40079820B (zh) 含叔胺药物物质的靶向递送
HK40104908A (zh) 一种包括针对人cldn18.2的抗体的抗体药物偶联物及其用途
CN121652224A (zh) 多肽偶联化合物、所得多肽偶联药物及其用途